AIM To evaluate the association between human leukocyte antigens (HLA) class I and therapeutic response to interferon-alpha in Croatian patients with chronic hepatitis C. METHODS HLA-A, -B, and -C genotyping was performed in 55 patients with sustained virological response and in 57 patients without sustained virological response to interferon-alpha therapy. Patients were treated in the period...

We evaluated the prophylactic and therapeutic efficacy of interferon alpha-2b, pegylated interferon alpha-2b, poly(I. C), and Ampligen against Modoc virus encephalitis in an animal model for flavivirus infections. All compounds significantly delayed virus-induced morbidity (paralysis) and mortality (due to progressive encephalitis). Viral load (as measured on day 7 postinfection) was significan...

context hepatocellular carcinoma (hcc) is a fatal disease. chronic hepatitis b virus (hbv) and/or hepatitis c virus (hcv) infection is the major cause of hcc. high viral replication rate and related hepatic/systematic inflammation are the major risk factors in hcc recurrence after hepatectomy or liver transplantation. evidence acquisition some of the carcinogenesis-related hbv mutations are als...

2. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman M, Zeuzem S, Craxi A, Raffanel C, Reindollar R, Rizzetto M, International Hepatitis Interventional Therapy Group: Retreatment of relapser after interferon therapy for chronic hepatitis C: An international randomized controlled trial of interferon plus ribavirin VS interferon alone. Hepatology 26:247A, 1997 (abstr) 3. Fer...

High-dose interferon-alpha remains the first-line treatment in the adjuvant therapy of metastatic melanoma. More recently, high-dose pegylated interferon-alpha-2b has been approved by the US Food and Drug Administration. Actually, an adjuvant therapy alternative to high-dose interferon-alpha is represented by ipilimumab. Moreover, combination therapy of IFN-alpha or ipilimumab with tyrosine kin...